Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Call Transcript
02:48pm, Monday, 08'th May 2023
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Rob Risinger - Chief Medical Offi
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
07:00am, Tuesday, 02'nd May 2023
NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicin
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating
07:33pm, Wednesday, 26'th Apr 2023
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating.
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
07:00am, Monday, 24'th Apr 2023
NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medic
BioXcel Therapeutics' Igalmi Commercial Launch: Not As Bad As Some May Think
06:45pm, Thursday, 16'th Mar 2023
BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch.
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
07:00am, Thursday, 23'rd Feb 2023
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
BioXcel BXCL701: Another Step Forward In The Race For An mCRPC Treatment
01:09am, Friday, 17'th Feb 2023
BioXcel has just published top-line data from the Phase IIa trial of BXCL701 for mSCNC with very promising results. These results position BXCL701 as a valuable asset for the first time.
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 22'nd Dec 2022
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
Why BioXCel Therapeutics Stock Jumped This Week
04:45pm, Thursday, 15'th Dec 2022
A couple of analysts recently upgraded their views on the biotech stock.
2 Beaten-Down Stocks to Watch Closely Next Year
09:53am, Tuesday, 06'th Dec 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Why BioXcel Therapeutics Stock Triumphed This Week
06:02pm, Friday, 02'nd Dec 2022
An analyst feels that the best is shortly to come for the company.
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
07:00am, Thursday, 01'st Dec 2022
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
Is This Soaring Growth Stock a Buy?
09:45am, Sunday, 20'th Nov 2022
The answer may depend on your risk tolerance.
Currently, several pharmaceutical companies are testing candidates' drugs and some of them are in the final stages of trials. The huge revenue potential is at stake in this race for the best anti-agit
BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
07:00am, Monday, 14'th Nov 2022
NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
